Ipilimumab and nivolumab have greater clinical activity when administered concurrently than either agent alone in patients with advanced melanoma, according to a study presented at ASCO 2013.
Cardiovascular fitness in middle-aged and older men is a strong independent predictor of incident lung and colorectal cancer, according to data presented at ASCO 2013.
When less expensive options are available, patients with cancer, oncologists, and the general public are in favor of saving money by using less costly treatments, found research presented at ASCO 2013.
Patients with HPV-associated resectable SCC of the oropharynx responded to induction chemo with paclitaxel, cisplatin, and cetuximab followed by low-dose radiation with cetuximab with minimal toxicities, found data presented at ASCO 2013.
Carboplatin plus first-line combination pemetrexed and bevacizumab therapy exhibits efficacy among elderly patients diagnosed with nonsquamous NSCLC, found data presented at ASCO 2013.
Adding the angiokinase inhibitor nintedanib to pemetrexed improves PFS among patients with non-squamous NSCLC for whom chemotherapy has failed, according to research presented at ASCO 2013.
Lambrolizumab is safe and exhibits anti-melanoma tumor activity, regardless of previous ipilimumab (IPI) treatment history, according to data presented at ASCO 2013.
The selective CDK4/6 inhibitor LY2835219 is safe in patients diagnosed with solid tumors, according to research presented at ASCO 2013.
Talimogene laherparepvec (T-VEC) represents a novel potential therapeutic option for patients with melanoma and regional or distant metastases, according to research presented at ASCO 2013.
Nivolumab produced durable overall survival and responses in a large cohort of patients with stage IV melanoma, found research presented at ASCO 2013.
Please login or register first to view this content.
